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Abstract: Purpose:  Acute oral tyrosine administration has been associated with increased
constant-load, submaximal exercise capacity in the heat.  This study sought to
determine whether self-paced exercise performance in the heat is enhanced with the
same tyrosine dosage.
Methods:  Following familiarisation, seven male endurance-trained volunteers,
unacclimated to exercise in the heat, performed two experimental trials in 30°C (60%
relative humidity) in a crossover fashion separated by at least 7 days.  Subjects
ingested 150 mg*kg body mass-1 tyrosine (TYR) or an isocaloric quantity of whey
powder (PLA) in 500 mL of sugar-free flavoured water in a randomised, double-blind
fashion.  Sixty minutes following drink ingestion subjects cycled for 60 min at 57 ± 4%
peak oxygen uptake (VO2peak), then performed a simulated cycling time-trial requiring
completion of an individualised target work quantity (393.1 ± 39.8 kJ).
Results:  The ratio of plasma tyrosine plus phenylalanine (tyrosine precursor): amino
acids competing for brain uptake (free-tryptophan, leucine, isoleucine, valine,
methionine, threonine, lysine) increased 2.5-fold from rest in TYR, and remained
elevated throughout exercise (P < 0.001), whereas it declined in PLA from rest to pre-
exercise (P = 0.004).  Time-trial power output (P = 0.869) and performance (34.8 ± 6.5
min and 35.2 ± 8.3 min in TYR and PLA, respectively; P = 0.4167) were similar
between trials.  Thermal sensation (P > 0.05), RPE (P > 0.05), core temperature (P =
0.860), skin temperature (P = 0.822) and heart rate (P = 0.314) did not differ between
trials.
Conclusion:  These data indicate that acute tyrosine administration did not influence
self-paced endurance exercise performance in the heat.  Plasma tyrosine availability is
apparently not a key determinant of fatigue processes under these conditions.
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Abstract 
Purpose:  Acute oral tyrosine administration has been associated with increased constant-
load, submaximal exercise capacity in the heat.  This study sought to determine whether self-
paced exercise performance in the heat is enhanced with the same tyrosine dosage.   
Methods:  Following familiarisation, seven male endurance-trained volunteers, unacclimated 
to exercise in the heat, performed two experimental trials in 30°C (60% relative humidity) in a 
crossover fashion separated by at least 7 days.  Subjects ingested 150 mg·kg body mass-1 
tyrosine (TYR) or an isocaloric quantity of whey powder (PLA) in 500 mL of sugar-free 
flavoured water in a randomised, double-blind fashion.  Sixty minutes following drink 
ingestion subjects cycled for 60 min at 57 ± 4% peak oxygen uptake ( Vɺ O2peak), then 
performed a simulated cycling time-trial requiring completion of an individualised target 
work quantity (393.1 ± 39.8 kJ).   
Results:  The ratio of plasma tyrosine plus phenylalanine (tyrosine precursor): amino acids 
competing for brain uptake (free-tryptophan, leucine, isoleucine, valine, methionine, 
threonine, lysine) increased 2.5-fold from rest in TYR, and remained elevated throughout 
exercise (P < 0.001), whereas it declined in PLA from rest to pre-exercise (P = 0.004).  Time-
trial power output (P = 0.869) and performance (34.8 ± 6.5 min and 35.2 ± 8.3 min in TYR 
and PLA, respectively; P = 0.4167) were similar between trials.  Thermal sensation (P > 
0.05), RPE (P > 0.05), core temperature (P = 0.860), skin temperature (P = 0.822) and heart 
rate (P = 0.314) did not differ between trials.   
Conclusion:  These data indicate that acute tyrosine administration did not influence self-
paced endurance exercise performance in the heat.  Plasma tyrosine availability is apparently 
not a key determinant of fatigue processes under these conditions. 
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Introduction  
Paragraph Number 1 Exercise performance is clearly impaired in high ambient temperature 
compared to cooler conditions (24, 35).  This impairment has been primarily attributed to 
fatigue caused by central nervous system changes, secondary to increased brain temperature 
(22), although peripheral factors including high skin temperature, dehydration and alterations 
in circulatory and thermoregulatory factors likely also contribute to this (30).  A definitive 
neurobiological cause has yet to be established for this central fatigue but one, or several, 
neurochemical systems are likely to be involved.  There is a well-defined role for the brain 
catecholamines dopamine and noradrenaline in increased motivation, arousal and reward (4), 
acute stress responses (28), motor initiation and control (14) and thermoregulation (9).  
Therefore, it is plausible these neurotransmitters modulate the central fatigue associated with 
prolonged exercise in the heat.   
 
Paragraph Number 2 The amino acid tyrosine is a nutritional substrate precursor for 
dopamine and noradrenaline.  Brain tyrosine concentrations are above the Km for tyrosine 
hydroxylase, the rate-limiting enzyme in catecholamine synthesis (8).  Catecholamine 
synthesis and release is also limited by neuronal firing rate so that during periods of low 
impulse flow tyrosine hydroxylase is highly susceptible to catecholamine end-product 
inhibition (8).  Microdialysis measurements in the rat confirm that augmentation of cerebral 
catecholamine release following systemic tyrosine injection, while under basal conditions, is 
generally limited in magnitude and duration (11).  In animals exposed to extreme 
environmental stress which substantially increases impulse flow through catecholamine 
neurons, such as nigrostriatal lesioning, electrical stimulation of cerebral catecholamine 
pathways or tail-shock, neurotransmitter turnover is elevated and tyrosine may be depleted in 
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some neuronal populations (5, 11, 17).  Tyrosine hydroxylase then exhibits increased affinity 
for tyrosine coupled with a decreased sensitivity to catecholamine end-product inhibition (29).  
Under these conditions, tyrosine administered to rats by injection or dietary means maintains 
cerebral tyrosine levels and augments central nervous system catecholamine turnover in 
activated neuronal populations (17, 34).  Impairments in locomotion, exploratory behaviour, 
memory and coping behaviour in rats exposed to acute, experimentally-induced stress such as 
tail-shock, heat or cold exposure are also countered by tyrosine administration (17, 18, 40).  
There is also a large body of evidence that cognitive, psychomotor and mood impairments 
and symptom intensity in humans induced by demanding environmental conditions such as 
cold, hypoxia or prolonged wakefulness, are countered by increasing plasma tyrosine 
availability via acute oral administration prior to exposure to the environmental conditions (1, 
19, 20, 23).  Evidence supporting an enhancement of exercise in humans following acute 
tyrosine supplementation is less clear.  Studies have generally failed to show benefits of acute 
tyrosine administration on exercise capacity, exercise performance, muscle strength and 
anaerobic power in temperate ambient conditions (7, 32, 33). There are mixed reports of the 
effectiveness of tyrosine supplementation prior to prolonged exercise in the heat. One recent 
study reported improved capacity to perform constant-load, submaximal intensity exercise in 
30°C heat (60% relative humidity)  following acute administration of 150 mg·kg body mass-1 
tyrosine (36) but a separate study using a similar protocol and tyrosine dosage failed to show 
an effect (37).   
 
Paragraph Number 3 Both Tumilty et al. (36) and Watson et al. (37) reported a marked 
increase in the ratio of plasma tyrosine: neutral amino acids which compete for brain uptake 
following supplementation.  This ratio is a key determinant of brain uptake of a single amino 
acid rather than the plasma concentration of the amino acid per se, as there are several neutral 
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amino acids competing for a shared, saturable carrier molecule across the blood-brain barrier 
(13). Therefore, increasing the plasma concentration of a single amino acid, or the 
concentration of competing amino acids, will increase or decrease the brain uptake of a given 
amino acid, respectively (13).   
 
Paragraph Number 4 To date, no study has assessed whether exercise performance (e.g. a 
time-trial) in the heat is augmented by high tyrosine availability despite evidence that tyrosine 
supplementation counters the adverse effects of challenging environmental conditions.  Due 
to the self-paced nature of a performance time-trial, which will be highly influenced by 
motivation and arousal, it is plausible that any improvements following tyrosine 
supplementation would be more apparent during this type of exercise trial compared to a 
constant-load capacity trial.  Therefore the present study was designed to test the hypothesis 
that acute tyrosine administration would improve exercise performance in the heat. 
 
Methods 
Subjects 
Paragraph Number 5 Eight male volunteers, unacclimated to exercise in the heat, and 
participating in regular endurance training at least four times per week, gave written informed 
consent to take part in the study.  This sample size provided sufficient power in a previous 
study to highlight an effect of tyrosine supplementation on prolonged exercise capacity in the 
heat (36).  One subject did not complete testing due to injury and the corresponding data was 
omitted from all statistical analysis.  The remaining seven subjects [six cyclists and one 
runner with regular experience of cycling; median age, 20 (range, 26) years; median stature, 
7 
 
1.83 (range, 0.13) m; mean ± SD for body mass, 77.9 ± 11.7 kg; peak oxygen uptake 
( Vɺ O2peak),  4.6 ± 0.6 L·min-1; peak power output attained during ramp test on a cycle 
ergometer to elicit Vɺ O2peak, 389 ± 44 W; maximal heart rate attained during ramp test, 186 ± 
8 beats·min-1] completed all trials.  Testing was carried out between October and June in 
Wales within the UK when the average daytime air temperature typically ranges between 3°C 
and 17 °C.  All subjects were resident here for at least one month before the commencement 
of testing.  The study was approved by Aberystwyth University Research Ethics Committee. 
 
Experimental procedures 
Paragraph Number 6 Subjects visited the lab on five separate occasions: an initial ramp test 
to determine peak power output, maximal heart rate and Vɺ O2peak using an online breath-by-
breath system (Jager Oxycon Pro, Hoechberg, Germany); 2 familiarisation visits; and 2 main 
experimental trials.  No strenuous or unaccustomed exercise was permitted for 24 h before 
each test.  Subjects were instructed to sleep for ≥ 8 h the night before each laboratory visit to 
ensure they were rested, and verbal confirmation of adherence to this was given on arrival for 
each test day.  All exercise was performed on an electrically braked cycle ergometer (Lode 
Excalibur Sport, Groningen, Netherlands).  Subjects wore comfortable clothing, which was 
kept consistent between trials, typically consisting of shorts, t-shirt and sports shoes or 
cycling shorts, short-sleeved cycling top and cycling shoes.  During the ramp test, power 
output was increased at a rate of 0.5 W·s-1 until the subject reached volitional exhaustion and 
Vɺ O2peak was determined as the highest oxygen uptake ( Vɺ O2) averaged over a 30 s period.  
Gas exchange threshold was identified using the v-slope method, determined as the first 
disproportionate increase in carbon dioxide output ( Vɺ CO2) relative to Vɺ O2 and an increase in 
the ventilatory equivalent for Vɺ O2 in relation to a levelling off or continued decrease in the 
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ventilatory equivalent for Vɺ CO2 (2).  Heart rate was recorded continuously during all trials 
using radiotelemetry (Polar RS800CX, Polar Electro Oy, Tampere, Finland) and the peak 
value measured during the ramp test was recorded as maximal heart rate.  At least 48 h 
elapsed between the ramp test and the first familiarisation visit and at least 7 d separated each 
of the remaining four trials.  The familiarisation visits were designed to appease any anxiety 
and to allow subjects to become accustomed to the time-trial protocol in the heat.  These visits 
were identical to the main experimental trials except that blood samples were not taken and 
the placebo drink (see below) was administered for both familiarisations.  All of the 
familiarisation and main trials commenced between 0630 h and 0930 h with each subject 
performing all four trials at the same time of day to control for diurnal variation.  Subjects 
recorded their food and drink intake for 48 h, and physical activity for 24 h, prior to the first 
familiarisation, and this enabled duplication prior to each subsequent visit.  After arriving at 
the laboratory following an overnight fast of at least 8 h, except for 500 mL of ordinary tap 
water which they drank exactly 2 h before arriving, subjects emptied their bladder into a 
pyrex beaker.  Urine volume was measured to the nearest mL before a 1.0 mL aliquot was 
frozen at -80°C for later measurement of osomolality, in duplicate, using freezing point 
depression (Osmostat 030, Gonotec, Berlin).  Nude, post-void body mass was measured to the 
nearest 0.1 kg (Seca 645, Seca GMB and Co., Hamburg, Germany), and stature was recorded 
(Holtain Ltd., stadiometer, Crymych, UK).  A rectal thermistor (Grant Instruments, 
Cambridge, England) was self-positioned by each subject 10 cm beyond the anal sphincter to 
enable core temperature measurement (Tcore) and surface skin temperature probes (Grant 
Instruments, Cambridge, England) were attached to the calf, thigh, chest and tricep using 
breathable medical tape (Hypafix, Bsn Medical, Hull, UK) so skin temperature (Tskin) could 
be measured.  Tcore and Tskin were recorded from an electronic data logger (Squirrel 
SQ2020, Grant Instruments, Cambridge, England) and from these data, mean weighted skin 
9 
 
temperature was calculated (27).  Subjects were seated for 15 min to minimize the effect of 
plasma volume changes before a 10.5 mL resting blood sample was obtained (Rest), with 
minimal stasis, from an antecubital vein, comprising 6 mL into a heparinised vacutainer and 
4.5 mL into a K3EDTA treated vacutainer (BD Vacutainer Systems, Plymouth, UK).  The 
experimental or placebo drink were administered in a randomised, double-blind and 
counterbalanced manner, before subjects were seated in a quiet, comfortable environment 
(20.5 ± 0.4 °C, 44 ± 6% relative humidity) for 1 h.  The experimental drink (TYR) contained 
150 mg·kg body mass-1 tyrosine (SHS international Ltd., Liverpool, UK) and 7 g vanilla 
flavouring (Myprotein.co.uk, Cheadle, Cheshire, UK) in 500 mL of fluid [ordinary tap water 
with 40% sugar-free lemon and lime squash (Morrisons, Bradford, UK)].  This tyrosine 
dosage was associated with increased exercise capacity in the heat in an earlier study (36).  
The placebo drink (PLA) contained the same fluid volume and content, with an isocaloric 
quantity of hydrolysed whey protein (Myprotein.co.uk, Cheadle, Cheshire, UK) instead of 
tyrosine (equating to 11.6 ± 1.6 g tyrosine or 6.1 ± 0.8 g whey protein; 22 ± 3 kcal) to ensure 
any performance effects of tyrosine were not due to the additional energy content of the 
experimental drink.  All drinks were coded and prepared by a separate drinks supervisor to 
ensure they were allocated in a double-blind manner.  Prior pilot work with three volunteers, 
who did not participate in this study, confirmed the drinks were indistinguishable in colour, 
taste and texture.  Care was taken to properly blend the mixtures, which were served in 
opaque drinking bottles, and were shaken vigorously immediately before ingestion.  At the 
end of the 1 h period, a second 10.5 mL blood sample (Pre) was taken before subjects entered 
the climate chamber (Design Environmental, Gwent, Wales).  Temperature and relative 
humidity of the chamber were maintained at  30.1 ± 0.2°C, 60 ± 0% respectively, and mean 
air velocity within the chamber was 0.26 ± 0.1 m·s-1 during all trials.  Once inside the 
chamber, subjects commenced cycling, without a warm up, at a constant power output 
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equivalent to 10% ∆ [power output requiring a Vɺ O2 that is 10% of the difference between the 
Vɺ O2 at the gas exchange threshold and Vɺ O2peak (16); 156 ± 24 W or 57 ± 4% Vɺ O2peak in this 
subject group] for 60 min.  The purpose of this exercise period was to induce hyperthermia 
before commencement of the time trial.  No information on time elapsed or motivational 
encouragement was given to the subjects throughout this exercise period.  Drinks (2 mL·kg 
body mass-1 ordinary tap water with 20% sugar-free lemon and lime squash) were provided at 
15, 30, 45 and 59 min.  At the end of the 60 min of cycling subjects were quickly removed to 
a chair directly adjacent to the cycle ergometer within the climate chamber, where a further 
10.5 mL blood sample was obtained (Post 60).  Subjects then remounted the cycle ergometer 
to perform a simulated cycling time-trial.  A maximum of 2 min elapsed between subjects 
dismounting the ergometer and the acquisition of the Post 60 blood sample.  The time taken to 
obtain this sample, and the time between the end of the 60 min of cycling and the 
commencement of the time-trial, was standardised for each individual subject during 
subsequent trials.  
 
Paragraph Number 7 The time-trial was based on a validated protocol used in previous 
research examining fatigue during prolonged exercise in the heat (38), and requires subjects to 
complete a set amount of work as quickly as possible.  Individual target work quantities were 
calculated for each subject as the amount of work which would be completed during 30 min 
cycling at 60% of the power output eliciting Vɺ O2peak during the initial ramp test (393.1 ± 39.8 
kJ in this group).  The cycle ergometer was set in linear mode (workload increases as 
pedalling rate increases) during the time-trial so that the power output, and hence the 
completed work, was directly related to pedalling cadence.  At the start of the time-trial 
subjects were given their target work quantities and instructed to complete the required 
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amount of work as quickly as possible and no other instructions or motivational 
encouragement was given throughout.  The control console for the ergometer was positioned 
on the bike frame, and the display was masked with non-transparent adhesive tape so that 
only the cumulative work portion of the console display was visible.  No further feedback on 
power output, cadence or time elapsed was provided throughout the time-trial.  A cumulative 
work target was also taped to the front of the ergometer handlebars, in full view of the 
subjects, which detailed the required work to achieve 25%, 50%, 75%, and 100% of their 
individual target.  Subjects were permitted to drink ad-libitum throughout (ordinary tap water 
with 20% sugar-free lemon and lime squash).  On completion of the time-trial subjects 
dismounted the cycle ergometer, moved quickly to the adjacent chair where a final 10.5 mL 
blood sample (Post TT) was obtained within a maximum of 2 min, and this time was also 
standardised for each individual subject during subsequent trials.  Subjects emptied their 
bladder, urine volume was again recorded to the nearest mL before a 1.0 mL aliquot was 
removed, then frozen at -80°C for later osmolality measurement. Finally, the thermistor and 
skin probes were removed before subjects showered, towelled dry and then were reweighed 
nude. 
 
Physiological measurements and blood analysis 
Paragraph Number 8 Heart rate, Tcore and Tskin were recorded every 10 min throughout 60 
min rest and 60 min of submaximal exercise.  Power output, heart rate, Tcore and Tskin were 
recorded at the start of the time-trial, and every 5 min throughout exercise.  RPE (3) and 
thermal sensation, using a 21 point scale ranging from -10 (cold impossible to bear) to +10 
(heat impossible to bear) (adapted from 25), were recorded every 10 min throughout 60 min 
submaximal exercise, after 5 min of the time-trial had elapsed, and then every 5 min 
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throughout the time-trial.  One minute expired gas samples were collected in Douglas bags at 
30 min and 50 min of the constant-load exercise period.  Oxygen and carbon dioxide 
concentrations were measured using a combined paramagnetic oxygen analyser and infrared 
carbon dioxide analyser (Series 4100 Xentra, Servomex, Crowborough, UK), which were 
calibrated before each trial using commercial gases (BOC, Guildford, UK), and expired 
volume was measured using a dry gas meter (Harvard Apparatus Ltd., Edenbridge, UK).  
Expired gases were used to estimate fat and carbohydrate utilisation and energy expenditure 
(26).  Final measurements of heart rate, Tcore, Tskin, RPE, thermal sensation, and power 
output were recorded immediately before subjects completed the time-trial.  Wind speed 
within the chamber was measured every 15 min of exercise as the mean value of four 
measurements taken from in front, behind, and to the left and right of each subject at head 
height while seated on the cycle ergometer, using a hand held anemometer (Kestrel 1000, 
Richard Paul Russell Ltd, Lymington, UK).   
 
Paragraph Number 9 Blood from the K3EDTA vacutainer was used to measure haematocrit, 
haemoglobin, lactate and glucose.  Whole blood was drawn into micro-capillary tubes, spun 
for 5 min at 14000 g using a Hawksley microcentrifuge (Haematospin 1400, Hawksley, 
Lancing, UK) and the separated red cell volume was measured using a Hawksley haematocrit 
tube reader, with a coefficient of variation of 0.8% for 10 repeated measurements on the same 
sample.  Haemoglobin was measured using an automated haematology analyser (Pentra 60C 
+, Horiba ABX Diagnostics, Northampton, UK), with a coefficient of variation of 0.3% for 10 
repeated measurements on the same sample standard, containing 14.0 g·L-1 haemoglobin.   
Haematocrit and haemoglobin measurements were used to estimate plasma volume changes 
(10).  Blood glucose and blood lactate concentrations were measured using an automated 
analyser (2300 Stat Plus, Yellow Spring Instrument Co., Ohio, USA), calibrated with standard 
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concentrations for glucose (0.00, and 50.00 mmol·L-1) and lactate (0.00 and 30.00 mmol·L-1).  
The coefficient of variation for 10 repeated measurements on a sample standard for blood 
glucose (6.14 mmol·L-1) and blood lactate (5.35 mmol·L-1) is 1.7% and 1.5%, respectively.  
The heparinised blood was immediately centrifuged at 1500 g for 10 minutes at 4°C, the 
plasma was then separated, and stored at -80°C for later analysis of amino acids using gas 
chromatography mass spectrometry (36). The coefficient of variation for the measurement of 
individual plasma amino acids using this technique is: leucine, 8.5%; isoleucine, 9.7%; valine, 
5.8%; methionine, 11.4%; threonine, 8.7%; lysine, 5.0%; the free fraction of tryptophan 
unbound from albumin (free-tryptophan), 5.2%; phenylalanine, 7.5% and tyrosine, 6.5%. 
Haematocrit was measured in triplicate and all remaining blood analyses were measured in 
duplicate. All blood parameters were corrected for plasma volume changes from baseline 
measurements at Rest.   
 
Statistical analyses 
Paragraph Number 10 A computerized statistical package was used to analyse all data (SPSS 
version 17.0, SPSS inc., Chicago, IL).  Normally distributed data are presented as mean ± SD.  
Time trial performance, urine osmolality and rate of body mass losses were examined using 
Student’s paired t-test. Cohen’s d effect size was calculated for the difference in time to 
complete the time-trial.  Differences in data throughout trials were compared using a repeated 
measures 2 factor (time × trial) analysis of variance (ANOVA).  Where significant differences 
were found, post hoc analysis was carried out using Student’s paired t-tests with the 
Bonferroni correction.  End of time-trial values were analysed separately using Student’s 
paired t-test to account for the different exercise duration between subjects and trials.  Non-
normally distributed data are presented as median (range), were analysed using Friedman’s 
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tests, and where appropriate, post hoc tests were carried out using Wilcoxon matched pairs 
tests with the Bonferroni correction.  Statistical significance was set at P < 0.05. 
 
Results 
Time-trial performance 
Paragraph Number 11 Following completion of all trials, three subjects reported they felt 
better or more motivated during the tyrosine trial, but could not distinguish between the TYR 
and PLA drinks, two subjects incorrectly thought they had received PLA when they had 
received TYR, and the remaining two subjects were unable to distinguish between trials, 
indicating successful drinks-blinding.  The coefficient of variation for time to complete the 
time-trial between the 2nd familiarisation trial and the PLA trial was 1.3% and there was no 
effect of trial order during the experimental trials (P = 0.313).  TYR did not influence the time 
to complete the time-trial (P = 0.417; effect size = 0.05; 34.8 ± 6.5 min in TYR and 35.2 ± 8.3 
min in PLA; Fig. 1A) and power output throughout the time-trial was similar in both trials (P 
= 0.869; Fig. 1B).  Subjects’ performance was even-paced up to 20 min of the time-trial (P = 
0.061), which represented the last time-point at which all subjects were still exercising. 
 
Blood analysis 
Paragraph Number 12 Plasma tyrosine concentration at Rest was similar in both trials (P = 
0.269; Fig. 2A), but was higher in TYR at all remaining sampling times (P < 0.01), while the 
concentration remained unchanged from Rest in PLA (P > 0.05).  Plasma phenylalanine 
concentration was unchanged at any time-point  in TYR (P > 0.05) but was elevated from 
Rest in PLA on completion of the time-trial (P < 0.01). There was no difference between 
trials in the ratio of plasma tyrosine plus phenylalanine: Σ(free-tryptophan; valine, leucine, 
isoleucine, threonine, methionine, lysine) at Rest (P = 0.838; Fig. 2B) but the ratio was higher 
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in TYR at all other time-points (P = 0.001).  TYR ingestion increased this ratio over 2.5-fold 
(P < 0.001) from Rest and remained elevated at all other sampling times (P < 0.001).  In PLA, 
there was a transient decline in this ratio from Rest to Pre-exercise (P = 0.004).  The plasma 
concentrations of the remaining individual amino acids analysed are provided in Table 1.  
Blood glucose concentration was unaffected by drink ingested (P > 0.05) or exercise (P = 
0.801) and was 5.3 ± 0.9 mmol·L-1 in both trials at Post TT.  At Post 60, blood lactate 
concentration had increased from Rest in both trials (P = 0.018), remaining elevated from 
Rest at Post TT (P = 0.018), but did not differ between trials [P > 0.05; 3.2 (range, 3.6) 
mmol·L-1 in TYR and 4.1 (range, 4.9) mmol·L-1 in PLA].  Plasma volume progressively 
declined, and to a similar extent in both trials, following drink ingestion (P < 0.05) reaching -
8.4 ± 6.0% in TYR and -9.1 ± 4.5% in PLA at end of time-trial.   
 
Temperature measurements 
Paragraph Number 13 Exercise caused a gradual increase in Tcore (P = 0.003) at a similar 
rate in both trials (P = 0.131; Fig. 3A).  At the end of the time-trial Tcore was 39.0 ± 0.7°C in 
TYR and 38.9 ± 0.6 in PLA (P = 0.474).  Tskin also increased during exercise (P = 0.012), 
plateauing after 20 min of constant-load exercise and after 15 min of time-trial (Fig. 3B).  The 
drink ingested had no influence on Tskin (P = 0.822) and there was no difference between 
trials in Tskin at end of the time-trial (34.8 ± 0.8°C in TYR and 35.0 ± 1.3°C in PLA; P = 
0.575).   
 
Heart rate 
Paragraph Number 14 There was a gradual increase in heart rate throughout exercise (Fig. 4; 
P < 0.001) which was unaffected by drink ingested (P = 0.314).  At end of the time-trial heart 
rate reached 100 ± 4% and 99 ± 4% of maximum in TYR and PLA, respectively (P = 0.729). 
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Urine analysis, fluid intake and body mass losses 
Paragraph Number 15 Pre-exercise urine osmolality suggested that subjects were similarly 
hydrated before both trials (P = 0.571; 329 ± 136 mosmol·kg-1 in TYR and 369 ± 148 
mosmol·kg-1 in PLA). After the time-trial urine osmolality was similar in each trial (198 ± 56 
mosmol·kg-1 in TYR and 325 ± 296 mosmol·kg-1 in PLA; P = 0.218) and unchanged from pre-
exercise (P = 0.202).  Subjects drank similar volumes of fluid during the time-trial in both 
trials (311.1 ± 114.4 mL in TYR and 363.0 ± 126.1 mL in PLA; P = 0.415).  By the end of the 
time-trial body mass losses, calculated from the difference between pre- and post-exercise 
body mass adjusted for fluid intake and urine output following initial weighing (2.9 ± 0.7% 
and 3.1 ± 1.1% of pre-exercise body mass in TYR and PLA, respectively; P = 0.528), and the 
rate of body mass loss (P = 0.436; 4.0 ± 1.0 kg·h-1 in TYR and 4.3 ± 1.6 kg·h-1 in PLA) were 
similar in both trials. 
 
Subjective ratings 
Paragraph Number 16 Expressed RPE gradually increased throughout exercise (Fig. 5A).  
There was no difference in RPE between trials at any time-point  (P > 0.05).  Median RPE at 
end of the time-trial was 19 (range, 3) arbitrary units in both trials (P = 0.689).  Thermal 
sensation gradually increased throughout exercise (Fig. 5B) and was the same in TYR and 
PLA throughout exercise (P > 0.05).  Median ratings at end of the time-trial were 7 (range, 5) 
arbitrary units in TYR, representing a rating between “Very hot, uncomfortable” and 
“Extremely hot, close to limit”.  Median thermal sensation at end of the time-trial in PLA was 
similar to TYR (P = 0.276), and was 8 (range, 6) arbitrary units representing a rating of 
“Extremely hot, close to limit”.  
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Estimated substrate usage 
Paragraph Number 17 Estimated fat (P = 0.253) and carbohydrate (P = 0.290) oxidation 
rates and estimated energy expenditure (P = 0.200) were unchanged from 30 to 50 min of 
constant-load submaximal exercise, and were similar in both trials (P > 0.05).   
 
Discussion 
Paragraph Number 18 Previous studies have examined the effect of tyrosine administration 
on exercise capacity in the heat in man (36, 37), but this is the first study to examine self-
paced exercise performance in the heat following acute oral tyrosine administration.  The 
present results demonstrate that, contrary to the hypothesis, acute administration of tyrosine 
did not improve self-paced exercise performance in the heat compared to a placebo containing 
an isocaloric quantity of hydrolysed whey protein.   
 
Paragraph Number 19 It was hypothesized that additional availability of tyrosine, a 
nutritional catecholamine precursor, would enhance exercise tolerance in the heat, as reported 
in an earlier study adopting a constant-load submaximal intensity exercise protocol (36).  
Additionally, it was expected that any performance effect of tyrosine administration would be 
more pronounced during a variable intensity time-trial, where subjects could self-pace the 
exercise and thus the subjective effort, compared to a constant-load trial.  The similar power 
output profiles in each time-trial in the present study, and therefore similar time to complete a 
set amount of work irrespective of drink ingested, suggests that tyrosine has no performance 
enhancing effect under the conditions of the present study.  This occurred despite a sound 
neurochemical basis for a benefit of tyrosine administration prior to performance of a time-
trial in the heat.  The clear impairment in exercise performance carried out in warm compared 
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to cooler ambient temperature (35) seems to be caused, in part, by alterations in cerebral 
function, caused by high brain temperature, resulting in reduced voluntary activation of 
muscle, increased subjective effort and a reduced will or “drive” to exercise (21, 22).  
Changes in central catecholamine activity are implicated in these processes due to their 
intrinsic connection with increased arousal and motivation (4), thermoregulation (9) and 
motor initiation and control (14).  Additionally, pharmacological augmentation of central 
catecholamine activity, via acute bupropion administration, improves simulated time-trial 
performance in the heat (30°C) but not in cooler conditions (18°C) (38), highlighting the 
importance of cerebral catecholamine activity in the ability to tolerate exercise with heat 
stress.   
 
Paragraph Number 20 The current protocol was employed on the basis that the combination 
of exercise and heat stress would represent a suitably demanding environment such that 
catecholamine neuronal sensitivity would be up-regulated to precursor availability.  The 
absence of effect on exercise performance in the present study occurred despite striking 
differences between the plasma amino acid profiles between trials following drink ingestion.  
The marked increase in the ratio of plasma tyrosine plus phenylalanine: amino acids 
competing for brain uptake following tyrosine administration was similar in magnitude to one 
study in which exercise capacity in the heat was prolonged by 15%, 1 hour following 
administration of 150 mg·kg-1 tyrosine (36).  This would favour the transport of tyrosine into 
the brain at the expense of other neutral amino acids which compete for uptake at the blood-
brain barrier (13).  This plasma ratio transiently declined following ingestion of the placebo 
mixture in the present study which would reduce brain entry of tyrosine (13).   
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Paragraph Number 21 At least one other study examining tyrosine administration prior to 
prolonged exercise in the heat provides support for the idea that exercise tolerance in the heat 
is enhanced following prior oral tyrosine administration (36).  But a separate study employing 
a similar tyrosine dosage and exercise protocol reported no effect (37).  It is not entirely clear 
why there are discrepant findings between the present study and previous work reporting 
benefit of tyrosine administration prior to exercise in the heat (36).   This could be related to 
the degree of arousal and stress induced by the different protocols adopted, and therefore the 
degree of activation of the central catecholaminergic system, and the factors involved in the 
regulation of tyrosine hydroxylase and catecholamine synthesis described above.  This may 
also explain why studies examining acute tyrosine administration in man prior to exercise in 
temperate conditions, have largely failed to report beneficial effects on exercise capacity (32), 
simulated time-trial performance performance (7) or muscle strength and anaerobic endurance 
(33).  While it seems apparent that, in man, exercise alone in the absence of heat stress is 
insufficiently demanding to up-regulate catecholamine precursor demand (7, 32), this does 
not adequately explain the discrepant findings between two studies adopting similar 
prolonged exercise protocols in the heat and tyrosine dosage (36, 37) and the underlying 
reasons for this require further clarification. 
 
Paragraph Number 22 As already mentioned, high brain catecholaminergic activity is 
associated with increased arousal and motivation (4) therefore an augmentation of central 
catecholamine following tyrosine administration might be expected to highlight differences in 
the power output profiles during the time-trial or the subjective response to exercise.  By 
definition, a self-paced time-trial allows the power output throughout the time-trial and thus 
the relative metabolic demand to be controlled from moment-to-moment.  The time-trial 
power output data in the present study suggest that subjects adopted an even-paced strategy 
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throughout the first 20 min of the time-trial, representing the last common time-point at which 
all subjects were still exercising, and that plasma tyrosine availability did not affect this 
pacing strategy.  Some investigators suggest that the adoption of a pacing strategy is 
necessary for the avoidance of catastrophic failure of the organism (31).  This is hypothesized 
to involve feedback and feed-forward control mechanisms in which the brain processes 
efferent neural commands based on previous experience of similar situations, in order to elicit 
the most appropriate power output and metabolic rate (31).  The present power output data 
demonstrate that even if a subconscious anticipation of the exercise power output was 
adopted, tyrosine had no additional effect on this compared to an isocaloric quantity of whey 
protein.  Furthermore, the similar values for RPE and thermal sensation, throughout 60 min of 
submaximal exercise and the simulated time-trial, suggests that the subjective interpretation 
of prolonged exercise in the heat cannot be manipulated by acutely increasing plasma tyrosine 
availability.   
 
Paragraph Number 23 Subjects were specifically administered an isocaloric quantity of 
whey protein as a placebo to clarify whether any effect of tyrosine administration was due to a 
peripheral (or central) effect of additional substrate or energy availability.  This could explain, 
in part, the differing results from previous tyrosine studies examining prolonged exercise in 
the heat (36, 37).  Estimated macronutrient oxidation rates were the same in both trials during 
50 min of submaximal exercise.  Also, subjects were euglycemic before commencing the 
constant-load exercise, the simulated time-trial and on the completion of the time-trial, 
suggesting that substrate supply did not limit exercise.  Reports of macronutrient oxidation 
rates in the heat are mixed, with some (12), but not all (21) studies reporting increased 
glycogen oxidation rates compared to cooler conditions.   However, subjects generally reach 
exhaustion during prolonged exercise in the heat with adequate muscle substrate and little 
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muscle metabolite accumulation, suggesting that these are not primary limitations under such 
conditions (21, 24), at least when the heat stress is uncompensable.  Blood lactate 
concentrations in the present study, although elevated following exercise as might be 
expected, were not suggestive of muscle concentrations which would markedly impair 
performance.   
 
Paragraph Number 24 If macronutrient and/or metabolite accumulation were not the primary 
cause of fatigue in the present study, then a direct fatiguing influence of hyperthermia seems 
probable.  Subjects in the present study were clearly hyperthermic in both trials and the Tcore 
values attained at the end of the time-trial are consistent with exhaustion values in subjects of 
similar fitness to the present cohort, following prolonged exercise in the heat (6).  As cerebral 
catecholamines have been implicated in heat loss processes during exercise (15), it might 
therefore be expected that some difference would be apparent in thermoregulatory responses 
to exercise between trials in the present study, if central catecholamine activity was 
augmented by tyrosine administration.  The similar data on Tcore, Tskin and rate of body 
mass losses, irrespective of drink ingested, implies that thermoregulatory processes were not 
affected despite a plasma amino acid profile, following ingestion of the experimental mixture, 
which would favour brain uptake of a direct catecholamine precursor (13).   
 
Paragraph Number 25 In summary, there was no effect of acute tyrosine administration on 
simulated time-trial performance in the heat compared to a placebo containing an isocaloric 
quantity of whey protein. The lack of an association between increased tyrosine availability 
and exercise performance suggests that, under the conditions of the present study, acutely 
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increasing plasma tyrosine availability does not influence fatigue processes when self-paced 
endurance exercise is performed with heat stress. 
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FIGURE 1—Mean ± SD (columns and vertical error bars) and individual (remaining 
individual lines) times to complete simulated cycling time-trial (A) and power output during 
time-trial, up to the last time point all subjects were exercising and value recorded at end of 
time-trial (B), in tyrosine (TYR) and placebo (PLA) trials.  Data are expressed as mean ± SD, 
(n = 7).  
 
FIGURE 2—Changes in plasma tyrosine concentration (A), tyrosine ratio [plasma 
concentration ratio of tyrosine plus phenylalanine: Σ(f-tryptophan; valine, leucine, isoleucine, 
threonine, methionine, lysine) (B) in tyrosine (TYR) and placebo (PLA) trials.  TT, time-trial.  
##Significant difference between trials, ††significantly different versus Rest in TYR, (P < 
0.01); §significantly different versus Rest in PLA, (P < 0.05). Data are expressed as mean ± 
SD, (n = 7).   
 
FIGURE 3—Core temperature (A) and mean weighted skin temperature (B) responses 
during 1 h rest, 60 min of constant-load submaximal exercise and simulated cycling time-trial 
(TT), up to the last time point that all subjects were exercising and value recorded at end of 
TT,  in tyrosine (TYR) and placebo (PLA)  trials.  **Significantly different versus start value 
in both trials, (P < 0.01).  Data are expressed as mean ± SD, (n = 7).   
 
FIGURE 4—Heart rate responses during 1 h rest, 60 min of constant-load submaximal 
exercise and simulated cycling time-trial (TT), up to the last time point that all subjects were 
exercising and value recorded at end of TT, in tyrosine (TYR) and placebo (PLA) trials. 
**Significantly different versus start value in both trials, (P < 0.01).  Data are expressed as 
mean ± SD, (n = 7).    
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FIGURE 5—RPE (A) and thermal sensation ratings (B) during 60 min of constant-load 
submaximal cycling and simulated cycling time-trial (TT), up to the last time point that all 
subjects were exercising and value recorded at end of TT,  in tyrosine (TYR)  and placebo 
(PLA) trials.  *Significantly different versus 10 min rating in both trials, (P < 0.05).  Data are 
expressed as mean ± SD, (n = 7). 
 
TABLE 1—Plasma amino acid concentrations in tyrosine (TYR) and placebo (PLA) trials. 
 
  TYR  PLA 
 Rest Pre- Post 60 Post TT  Rest Pre- Post 60 Post TT 
Amino acids (µmol·L
-1
)          
f-Tryptophan 149 (107) 152 (28) 150 (77) 162 (127)  155 (93) 160 (49) 154 (93) 172 (77) 
Valine  158 (69) 135 (51) 159 (81) 143 (73)  165 (85) 166 (53) 144 (102) 161 (108) 
Leucine 146 (74) 105 (79)§ 130 (89) 131 (117)  154 (128) 181 (83)# 135 (115) 166 (84) 
Isoleucine 83 (42) 66 (38)§ 62 (35) 73 (43)  77 (75) 97 (42)# 76 (55) 86 (29)# 
Threonine  92 (46) 99 (58) 96 (44) 92 (68)  120 (45) 118 (54) 104 (51) 121 (55) 
Methionine 30 (9) 27 (9) 28 (9) 34 (22)   30 (9) 30 (7)# 31 (144) 36 (15)§ 
Lysine 254 (115) 251 (131) 216 (98) 215 (178)  226 (161) 276 (139) 253 (147) 246 (112) 
Σ (mmol·L-1) 1.0 (0.4) 1.0 (0.3) 0.9 (0.3) 1.0 (0.3)  0.9 (0.3) 0.8 (0.3)# 0.9 (0.3) 0.8 (0.5) 
Values are median (range). f-Tryptophan, free tryptophan; Σ, Σ(valine, leucine, isoleucine, threonine, methionine, lysine).  §significantly 
different from Rest in same trial, (P < 0.05; n = 7);  #Significant difference between trials, (P < 0.05; n = 7).  
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